Correction Issued for Real-World Osilodrostat Study in Adrenal Cushing Syndrome
A correction has been published for a real-world study on osilodrostat's efficacy and safety in adrenal Cushing syndrome.
Summary
The Journal of Clinical Endocrinology & Metabolism has issued a formal correction to a previously published international real-world study examining osilodrostat — a steroidogenesis inhibitor — in patients with adrenal Cushing syndrome. Osilodrostat works by blocking cortisol production and has been used in patients where surgery is not an option or has failed. The original study assessed how well the drug performs outside of controlled trial settings, reflecting everyday clinical use across multiple countries. Corrections to published research are a normal part of scientific integrity, ensuring that the data and conclusions available to clinicians and researchers remain accurate. The nature of the specific correction is not detailed in the available record, limiting full assessment of its clinical impact. Readers relying on the original findings should consult the updated version.
Detailed Summary
Corrections to published studies are an important, if often overlooked, component of scientific rigor. When real-world data informs clinical practice — especially for rare and complex endocrine conditions — accuracy is paramount. This notice flags a correction to a previously published international real-world study on osilodrostat in adrenal Cushing syndrome, published in the Journal of Clinical Endocrinology & Metabolism.
Osilodrostat (brand name Isturisa) is a potent inhibitor of 11β-hydroxylase, the enzyme responsible for the final step of cortisol biosynthesis. It is approved for adults with Cushing's disease and has been studied in adrenal forms of the condition, where excess cortisol originates from adrenal tumors rather than pituitary ACTH overproduction. Real-world studies are critical for understanding how drugs perform beyond the controlled conditions of randomized trials.
The original study from which this correction derives examined osilodrostat's effectiveness and tolerability across multiple international centers, providing clinicians with practical data on cortisol normalization rates, adverse effects, and patient outcomes in routine care. Such studies help bridge the gap between trial evidence and everyday clinical decision-making for a rare disease with limited treatment options.
The correction itself, published online ahead of print in May 2026, does not include authors or a detailed description of what was amended. Without access to the full correction notice, it is not possible to determine whether the changes affect primary efficacy data, safety reporting, patient demographics, or statistical analyses.
For clinicians managing patients with adrenal Cushing syndrome who have referenced the original study, it is advisable to review the corrected version before applying its findings. While corrections do not necessarily invalidate a study's conclusions, they can meaningfully alter interpretation of results, particularly in the context of dosing guidance or safety monitoring protocols.
Key Findings
- A formal correction has been issued for a real-world osilodrostat study in adrenal Cushing syndrome.
- Osilodrostat inhibits cortisol synthesis and is used when surgery is not feasible or has failed.
- The nature and clinical impact of the correction are not specified in the available record.
- Clinicians using this study to guide practice should consult the updated corrected publication.
Methodology
This is a published correction notice rather than an original study. The underlying research was a real-world, international, multi-center observational study. No methodological details of the correction itself are available from the abstract record.
Study Limitations
The summary is based on the abstract only, which contains no substantive information about the nature or scope of the correction. The original study's findings, and how they may be altered by this correction, cannot be assessed without full-text access. No authors are listed for this correction notice.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.